CymaBay Therapeutics (Nasdaq:CBAY) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

CBAY Panoramica delle azioni

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases.

Informazioni sull'azienda

CBAY analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	2/6
Prestazioni passate	0/6
Salute finanziaria	4/6
Dividendi	0/6

Premi

Negoziato a 86.9% al di sotto della nostra stima del suo valore equo

Si prevede che i ricavi cresceranno 50.87% all'anno

Analisi del rischio

Gli azionisti sono stati diluiti nell'ultimo anno

Attualmente non redditizio e non si prevede che diventerà redditizio nei prossimi 3 anni

CymaBay Therapeutics, Inc. Concorrenti

Avadel Pharmaceuticals

NasdaqGM:AVDL

US$1.6b

Axsome Therapeutics

NasdaqGM:AXSM

US$4.2b

Nuvation Bio

NYSE:NUVB

US$717.8m

Intra-Cellular Therapies

NasdaqGS:ITCI

US$7.9b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per CymaBay Therapeutics
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$32.48
Massimo di 52 settimane	US$32.50
Minimo di 52 settimane	US$7.26
Beta	0.32
1Variazione di 1 mese	0.87%
Variazione a 3 mesi	40.67%
Variazione di 1 anno	262.91%
3Variazione a 3 anni	607.63%
Variazione a 5 anni	147.94%
Variazione dall'IPO	260.89%

Notizie e aggiornamenti recenti

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Analysts Just Slashed Next Year's Revenue Estimates By 17%

Feb 15

Recent updates

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Analysts Just Slashed Next Year's Revenue Estimates By 17%

Feb 15

Analysts' Revenue Estimates For CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Are Surging Higher

Dec 22

Rendimenti per gli azionisti

	CBAY	US Pharmaceuticals	US Mercato
7D	0.03%	2.2%	1.2%
1Y	262.9%	19.0%	25.9%

Ritorno vs Industria: CBAY ha superato il US Pharmaceuticals che ha restituito 16 % nell'ultimo anno.

Rendimento vs Mercato: CBAY ha superato il mercato US che ha restituito 25.6 % nell'ultimo anno.

Volatilità dei prezzi

Is CBAY's price volatile compared to industry and market?
CBAY volatility
CBAY Average Weekly Movement	8.2%
Pharmaceuticals Industry Average Movement	10.5%
Market Average Movement	6.4%
10% most volatile stocks in US Market	15.2%
10% least volatile stocks in US Market	3.2%

Prezzo delle azioni stabile: Il prezzo delle azioni di CBAY è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 8% ) di CBAY è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1988	101	Sujal Shah	www.cymabay.com

CymaBay Therapeutics, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di CymaBay Therapeutics con la sua capitalizzazione di mercato?
CBAY statistiche fondamentali
Capitalizzazione di mercato	US$3.73b
Guadagni(TTM)	-US$105.37m
Ricavi(TTM)	US$31.07m

120.0x

Rapporto P/S

-35.4x

Rapporto P/E

CBAY è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
CBAY Conto economico (TTM)
Ricavi	US$31.07m
Costo del fatturato	US$80.80m
Profitto lordo	-US$49.73m
Altre spese	US$55.64m
Guadagni	-US$105.37m

Ultimi guadagni dichiarati

Dec 31, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)	-0.92
Margine lordo	-160.03%
Margine di profitto netto	-339.10%
Rapporto debito/patrimonio netto	37.4%

Come si è comportato CBAY nel lungo periodo?

Vedi performance storica e confronto

CBAY Panoramica delle azioni

Premi

Analisi del rischio

CymaBay Therapeutics, Inc. Concorrenti

NasdaqGM:AVDL

US$1.6b

NasdaqGM:AXSM

US$4.2b

NYSE:NUVB

US$717.8m

NasdaqGS:ITCI

US$7.9b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

CymaBay Therapeutics Files Form 15

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of CymaBay Therapeutics, Inc. (NasdaqGS:CBAY).

President exercised options to buy US$4.5m worth of stock.

CymaBay Therapeutics, Inc. Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis

No longer forecast to breakeven

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Analysts Just Slashed Next Year's Revenue Estimates By 17%

Recent updates

CymaBay Therapeutics Files Form 15

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of CymaBay Therapeutics, Inc. (NasdaqGS:CBAY).

President exercised options to buy US$4.5m worth of stock.

CymaBay Therapeutics, Inc. Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis

No longer forecast to breakeven

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Analysts Just Slashed Next Year's Revenue Estimates By 17%

Price target increased by 8.5% to US$31.07

CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis

CymaBay Therapeutics, Inc. Announces Executive Changes

Forecast to breakeven in 2026

Analysts' Revenue Estimates For CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Are Surging Higher

Cymabay Therapeutics, Inc. and Lewis Stuart, Chief Commercial Officer, Mutually Agrees on Cease to Be an Officer and Employee Effective December 29, 2023

Cymabay Therapeutics, Inc. Submits New Drug Application to FDA for Seladelpar for the Treatment of Primary Biliary Cholangitis

President exercised options and sold US$973k worth of stock

President notifies of intention to sell stock

Price target increased by 7.5% to US$24.82

New minor risk - Profitability

CymaBay Therapeutics, Inc. Announces Publication of Two-Year Safety and Efficacy Results of Seladelpar in Patients with Primary Biliary Cholangitis

CymaBay Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

President exercised options and sold US$597k worth of stock

General Counsel notifies of intention to sell stock

CymaBay Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $224.999939 million.

Price target increased by 17% to US$21.27

Insider notifies of intention to sell stock

Consensus revenue estimates increase by 156%

Price target increased by 8.0% to US$17.64

New minor risk - Profitability

CymaBay Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Consensus revenue estimates fall by 15%

Price target increased by 8.5% to US$15.56

Insider notifies of intention to sell stock

Price target increased by 8.2% to US$14.67

New minor risk - Share price stability

Insider notifies of intention to sell stock

General Counsel notifies of intention to sell stock

Consensus revenue estimates fall by 40%

CymaBay Therapeutics, Inc. to Report Q1, 2023 Results on May 15, 2023

CymaBay Therapeutics, Inc. Appoints Harish Shantharam as Chief Financial Officer

Executive Officer notifies of intention to sell stock

Consensus revenue estimates increase by 24%

Price target increased by 11% to US$13.56

Price target increased by 8.1% to US$11.63

CymaBay Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $84.999785 million.

CymaBay Therapeutics (NASDAQ:CBAY) Has Debt But No Earnings; Should You Worry?

CymaBay Therapeutics Presents Additional Analyses from Clinical Studies of Seladelpar for Patients with Primary Biliary Cholangitis

CymaBay Therapeutics, Inc. Announces Executive Changes

CymaBay Therapeutics GAAP EPS of -$0.31 misses by $0.01

CymaBay Therapeutics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Cymabay Completes Enrollment for the Response Global Phase 3 Study Evaluating Seladelpar for Patients with Primary Biliary Cholangitis

Is CymaBay Therapeutics (NASDAQ:CBAY) Weighed On By Its Debt Load?

CymaBay: Long-Term Potential Based On Prior PBC Trial Results

CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from Russell 2000 Dynamic Index

CymaBay Therapeutics, Inc. Presents Positive PBC Data at the International Liver Congress 2022

President recently bought US$100k worth of stock

CymaBay Therapeutics, Inc. Presents New Findings That Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free Survival

Price target decreased to US$10.50

Insufficient new directors

CymaBay Therapeutics, Inc. Appoints Éric Lefebvre to the Audit Committee and the Nominating and Corporate Governance Committee of the Board

Is CymaBay Therapeutics (NASDAQ:CBAY) Using Debt In A Risky Way?